Raloxifene Drops Breast Cancer Incidence
A U.S. study of raloxifene found women had more than a 50 percent reduction in breast cancer incidence beyond the first four years of treatment.
The Multiple Outcomes of Raloxifene Evaluation, or MORE trial, found that in postmenopausal women with osteoporosis, four years of raloxifene — under the brand name Evista — was associated with a 72 percent reduction in breast cancer incidence compared with a placebo.
In the Continuing Outcomes Relevant to Evista, or CORE trial, more than 4,000 women who had been part of the MORE trial continued taking raloxifene or a placebo, depending on which group they were in.
Silvana Martino, of the Cancer Institute Medical Group in Santa Monica, Calif., found after four years of the CORE trial, incidence of invasive breast cancer for women taking raloxifene was reduced by 59 percent compared with women taking the placebo.
The findings are published in Wednesday’s Journal of the National Cancer Institute.